DeepMed Research

Abacavir

Generic Name: Abacavir

Brand Names: Epzicom, Kivexa, Triumeq, Trizivir, Ziagen

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₈N_₆O

CAS Number: 136470-78-5

Unique Ingredient Identifier: WR2TIP26VS

Background: Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.

Indication: Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 80

Registration Number: NCT00002213

Locations: 🇺🇸
Niaid / Nih, Bethesda, Maryland, United States
🇺🇸
Northwestern Univ Med School AIDS Treatment Unit, Chicago, Illinois, United States
🇺🇸
Univ Int Med Assoc Inc / Holmes Hosp / U of Cincinnati, Cincinnati, Ohio, United States

and more 6 locations

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

Phase 4

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 230

Registration Number: NCT00005106

Locations: 🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸
THE Clinic, Los Angeles, California, United States
🇺🇸
Maxine Liggins, Los Angeles, California, United States

and more 36 locations

Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

Phase 4

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 150

Registration Number: NCT00005018

Locations: 🇺🇸
East Bay AIDS Ctr, Berkeley, California, United States
🇺🇸
Altamed Medical Health Services, Los Angeles, California, United States
🇺🇸
Gary Richmond MD, Fort Lauderdale, Florida, United States

and more 20 locations

A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00002390

Locations: 🇩🇪
Universitatsklinikurn Frankfurt, Frankfurt, Germany
🇫🇷
Group Hospier Pitie-Salpetriere / Maladies Infec et Trop, Paris Cedex 13, France
🇩🇪
Universitat Erlangen, Erlangen, Germany

and more 3 locations

A Study of 1592U89 in HIV-Infected Adults

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00002200

Locations: 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States

The Effect of Teaching HIV-Infected Patients About HIV and Treatment

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 200

Registration Number: NCT00002409

Locations: 🇺🇸
Specialty Med Care Ctrs of South Florida Inc, Miami, Florida, United States
🇺🇸
Rush Med College / Dept of Infectious Diseases, Chicago, Illinois, United States
🇺🇸
Santa Rosa Med Ctr / Baptist Med Ctr, San Antonio, Texas, United States

and more 22 locations

A Study of 1592U89 in HIV-Infected Patients

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 48

Registration Number: NCT00002388

Locations: 🇺🇸
Albany Med College / Albany Med Ctr Hosp, Albany, New York, United States
🇺🇸
Evanston Hosp / Clinical Pharmacology Unit, Evanston, Illinois, United States
🇺🇸
Fenway Community Health Ctr / Research Dept, Boston, Massachusetts, United States

A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 60

Registration Number: NCT00002183

Locations: 🇺🇸
UCSD, San Diego, California, United States
🇺🇸
Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States

A Study of 1592U89 in HIV-Infected Children

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 250

Registration Number: NCT00002197

Locations: 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

Phase 3

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 624

Registration Number: NCT00009061

Locations: 🇺🇸
North Jersey Community Research Initiative, Newark, New Jersey, United States
🇺🇸
Nicholas Bellos, Dallas, Texas, United States
🇺🇸
Therafirst Med Ctr, Fort Lauderdale, Florida, United States

and more 34 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy